Clinical development of antivirals against SARS-CoV-2 and its variants
The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Current Research in Microbial Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666517423000299 |
| _version_ | 1797401630350508032 |
|---|---|
| author | Qiaoshuai Lan Yan Yan Guangxu Zhang Shuai Xia Jie Zhou Lu Lu Shibo Jiang |
| author_facet | Qiaoshuai Lan Yan Yan Guangxu Zhang Shuai Xia Jie Zhou Lu Lu Shibo Jiang |
| author_sort | Qiaoshuai Lan |
| collection | DOAJ |
| description | The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants. |
| first_indexed | 2024-03-09T02:12:47Z |
| format | Article |
| id | doaj.art-7f8bb778828a49ba8a5171da7583063e |
| institution | Directory Open Access Journal |
| issn | 2666-5174 |
| language | English |
| last_indexed | 2024-03-09T02:12:47Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Microbial Sciences |
| spelling | doaj.art-7f8bb778828a49ba8a5171da7583063e2023-12-07T05:31:06ZengElsevierCurrent Research in Microbial Sciences2666-51742024-01-016100208Clinical development of antivirals against SARS-CoV-2 and its variantsQiaoshuai Lan0Yan Yan1Guangxu Zhang2Shuai Xia3Jie Zhou4Lu Lu5Shibo Jiang6Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, ChinaKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, ChinaKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, ChinaKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, ChinaCentre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China; Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, ChinaKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China; Corresponding authors.Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China; Corresponding authors.The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.http://www.sciencedirect.com/science/article/pii/S2666517423000299SARS-CoV-2VariantsCOVID-19AntiviralsHost factorViral factor |
| spellingShingle | Qiaoshuai Lan Yan Yan Guangxu Zhang Shuai Xia Jie Zhou Lu Lu Shibo Jiang Clinical development of antivirals against SARS-CoV-2 and its variants Current Research in Microbial Sciences SARS-CoV-2 Variants COVID-19 Antivirals Host factor Viral factor |
| title | Clinical development of antivirals against SARS-CoV-2 and its variants |
| title_full | Clinical development of antivirals against SARS-CoV-2 and its variants |
| title_fullStr | Clinical development of antivirals against SARS-CoV-2 and its variants |
| title_full_unstemmed | Clinical development of antivirals against SARS-CoV-2 and its variants |
| title_short | Clinical development of antivirals against SARS-CoV-2 and its variants |
| title_sort | clinical development of antivirals against sars cov 2 and its variants |
| topic | SARS-CoV-2 Variants COVID-19 Antivirals Host factor Viral factor |
| url | http://www.sciencedirect.com/science/article/pii/S2666517423000299 |
| work_keys_str_mv | AT qiaoshuailan clinicaldevelopmentofantiviralsagainstsarscov2anditsvariants AT yanyan clinicaldevelopmentofantiviralsagainstsarscov2anditsvariants AT guangxuzhang clinicaldevelopmentofantiviralsagainstsarscov2anditsvariants AT shuaixia clinicaldevelopmentofantiviralsagainstsarscov2anditsvariants AT jiezhou clinicaldevelopmentofantiviralsagainstsarscov2anditsvariants AT lulu clinicaldevelopmentofantiviralsagainstsarscov2anditsvariants AT shibojiang clinicaldevelopmentofantiviralsagainstsarscov2anditsvariants |